Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 3;14(9):939.
doi: 10.3390/jpm14090939.

Addressing the Ethnicity Gap in Catechol O-Methyl Transferase Inhibitor Trials in Parkinson's Disease: A Review of Available Global Data

Karolina Poplawska-Domaszewicz  1   2 , Naomi Limbachiya  2   3 , Mubasher Qamar  2   3 , Lucia Batzu  2   3 , Shelley Jones  3 , Anna Sauerbier  2   4 , Silvia Rota  2   3 , Yue Hui Lau  5 , K Ray Chaudhuri  2   3
Affiliations

Addressing the Ethnicity Gap in Catechol O-Methyl Transferase Inhibitor Trials in Parkinson's Disease: A Review of Available Global Data

Karolina Poplawska-Domaszewicz et al. J Pers Med. .

Abstract

Catechol-O-methyltransferase inhibitors (COMT-Is) have significantly improved the quality of life and symptom management for those at advanced stages of Parkinson's Disease (PD). Given that PD is one of the fastest-growing neurodegenerative diseases worldwide, there is a need to establish a clear framework for the systematic distribution of COMT-Is, considering inter-individual and intra-individual variations in patient response. One major barrier to this is the underrepresentation of ethnic minority participants in clinical trials investigating COMT-Is. To investigate this, we performed a narrative review. We searched PubMed for clinical trials investigating COMT-Is in patients with PD and examined the ethnic diversity of cohorts. A total of 63 articles were identified, with 34 trials found to match our inclusion criteria. Among the 34 trials meeting our inclusion criteria, only 8 reported participants' ethnic backgrounds. Our findings reveal a consistent underrepresentation of ethnic minority groups in trials investigating COMT-Is in PD cohorts-a trend that reflects broader concerns across clinical research. In this review, we explore potential reasons for the underrepresentation of ethnic minorities in clinical trials and propose strategies to address this issue.

Keywords: COMT; Parkinson’s disease; diversity; pharmacogenetics; polymorphism.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Figure 1
Figure 1
A summary and schematic representation of the various roles of Catechol O-Methyl Transferase and its functional consequences in Parkinson’s disease.
Figure 2
Figure 2
Narrative review article selection procedure.
See this image and copyright information in PMC

References

    1. Dorsey E.R., Elbaz A., Nichols E., Abbasi N., Abd-Allah F., Abdelalim A., Adsuar J.C., Ansha M.G., Brayne C., Choi J.-Y.J., et al. Global, regional, and national burden of Parkinson’s disease, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939–953. doi: 10.1016/S1474-4422(18)30295-3. - DOI - PMC - PubMed
    1. Ben-Shlomo Y. The epidemiology of Parkinson’s disease. Lancet. 2024;403:283–292. doi: 10.1016/S0140-6736(23)01419-8. - DOI - PMC - PubMed
    1. Jenner P., Rocha J.-F., Ferreira J.J., Rascol O., Soares-Da-Silva P. Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: The role of opicapone. Expert. Rev. Neurother. 2021;21:1019–1033. doi: 10.1080/14737175.2021.1968298. - DOI - PubMed
    1. Onozawa R., Tsugawa J., Tsuboi Y., Fukae J., Mishima T., Fujioka S. The impact of early morning off in Parkinson’s disease on patient quality of life and caregiver burden. J. Neurol. Sci. 2016;364:1–5. doi: 10.1016/j.jns.2016.02.066. - DOI - PubMed
    1. Artusi C.A., Sarro L., Imbalzano G., Fabbri M., Lopiano L. Safety and efficacy of tolcapone in Parkinsons disease: Systematic review. Eur. J. Clin. Pharmacol. 2021;77:817–829. doi: 10.1007/s00228-020-03081-x. - DOI - PMC - PubMed

LinkOut - more resources